BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 12673713)

  • 1. Cytokeratin expression patterns in low-grade papillary urothelial neoplasms of the urinary bladder.
    Ramos D; Navarro S; Villamón R; Gil-Salom M; Llombart-Bosch A
    Cancer; 2003 Apr; 97(8):1876-83. PubMed ID: 12673713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the WHO/ISUP classification and cytokeratin 20 expression in predicting the behavior of low-grade papillary urothelial tumors. World/Health Organization/Internattional Society of Urologic Pathology.
    Alsheikh A; Mohamedali Z; Jones E; Masterson J; Gilks CB
    Mod Pathol; 2001 Apr; 14(4):267-72. PubMed ID: 11301341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship of cytokeratin 20 and CD44 protein expression with WHO/ISUP grade in pTa and pT1 papillary urothelial neoplasia.
    Desai S; Lim SD; Jimenez RE; Chun T; Keane TE; McKenney JK; Zavala-Pompa A; Cohen C; Young RH; Amin MB
    Mod Pathol; 2000 Dec; 13(12):1315-23. PubMed ID: 11144928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histologic grading of noninvasive papillary urothelial tumors: validation of the 1998 WHO/ISUP system by immunophenotyping and follow-up.
    Yin H; Leong AS
    Am J Clin Pathol; 2004 May; 121(5):679-87. PubMed ID: 15151208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparative study of P 53, Bcl-2, and C-erbB-2 expression in low-grade papillary bladder tumors].
    Ramos Soler D; Navarro Fos S; Villamón Fort R; Gil Salom M; Llombart Bosch A
    Arch Esp Urol; 2003 Apr; 56(3):277-85. PubMed ID: 12768988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Micropapillary variant of urothelial carcinoma of the urinary bladder; a clinicopathological and immunohistochemical study.
    Samaratunga H; Khoo K
    Histopathology; 2004 Jul; 45(1):55-64. PubMed ID: 15228444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strong immunohistochemical expression of fibroblast growth factor receptor 3, superficial staining pattern of cytokeratin 20, and low proliferative activity define those papillary urothelial neoplasms of low malignant potential that do not recur.
    Barbisan F; Santinelli A; Mazzucchelli R; Lopez-Beltran A; Cheng L; Scarpelli M; van der Kwast T; Montironi R
    Cancer; 2008 Feb; 112(3):636-44. PubMed ID: 18072261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours.
    van Oers JM; Wild PJ; Burger M; Denzinger S; Stoehr R; Rosskopf E; Hofstaedter F; Steyerberg EW; Klinkhammer-Schalke M; Zwarthoff EC; van der Kwast TH; Hartmann A
    Eur Urol; 2007 Sep; 52(3):760-8. PubMed ID: 17240035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proliferative activity is the most significant predictor of recurrence in noninvasive papillary urothelial neoplasms of low malignant potential and grade 1 papillary carcinomas of the bladder.
    Pich A; Chiusa L; Formiconi A; Galliano D; Bortolin P; Comino A; Navone R
    Cancer; 2002 Aug; 95(4):784-90. PubMed ID: 12209722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of the 2004 WHO/ISUP classification for prediction of recurrence, progression, and cancer-specific mortality of non-muscle-invasive urothelial tumors of the urinary bladder: a clinicopathologic study of 1,515 cases.
    Pan CC; Chang YH; Chen KK; Yu HJ; Sun CH; Ho DM
    Am J Clin Pathol; 2010 May; 133(5):788-95. PubMed ID: 20395527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of p53 nuclear accumulation in low- and high-grade (WHO/ISUP classification) transitional papillary carcinomas of the bladder for tumor recurrence and progression.
    Vardar E; Gunlusoy B; Minareci S; Postaci H; Ayder AR
    Urol Int; 2006; 77(1):27-33. PubMed ID: 16825812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokeratin 20 as an immunocytochemical marker for detection of urothelial carcinoma in atypical cytology: preliminary retrospective study on archived urine slides.
    Lin S; Hirschowitz SL; Williams C; Shintako P; Said J; Rao JY
    Cancer Detect Prev; 2001; 25(2):202-9. PubMed ID: 11341356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of residual tumor cells in bladder biopsy specimens: pitfalls in the interpretation of cytokeratin stains.
    Tamas EF; Epstein JI
    Am J Surg Pathol; 2007 Mar; 31(3):390-7. PubMed ID: 17325480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer.
    Bertz S; Otto W; Denzinger S; Wieland WF; Burger M; Stöhr R; Link S; Hofstädter F; Hartmann A
    Eur Urol; 2014 Jan; 65(1):218-26. PubMed ID: 22633802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer.
    Tzai TS; Tsai YS; Chow NH
    Urol Oncol; 2004; 22(2):112-8. PubMed ID: 15082007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of cytokeratin 20 redefines urothelial papillomas of the bladder.
    Harnden P; Mahmood N; Southgate J
    Lancet; 1999 Mar; 353(9157):974-7. PubMed ID: 10459907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder.
    Quintero A; Alvarez-Kindelan J; Luque RJ; Gonzalez-Campora R; Requena MJ; Montironi R; Lopez-Beltran A
    J Clin Pathol; 2006 Jan; 59(1):83-8. PubMed ID: 16394286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance in substaging ofT1 urinary bladder urothelial carcinoma on transurethral resection.
    Chang WC; Chang YH; Pan CC
    Am J Surg Pathol; 2012 Mar; 36(3):454-61. PubMed ID: 22261706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoxia-inducible factor-1alpha expression correlates with focal macrophage infiltration, angiogenesis and unfavourable prognosis in urothelial carcinoma.
    Chai CY; Chen WT; Hung WC; Kang WY; Huang YC; Su YC; Yang CH
    J Clin Pathol; 2008 May; 61(5):658-64. PubMed ID: 17908805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Motility-related protein 1 (MRP-1/CD9) expression in urothelial bladder carcinoma and its relation to tumor recurrence and progression.
    Mhawech P; Herrmann F; Coassin M; Guillou L; Iselin CE
    Cancer; 2003 Oct; 98(8):1649-57. PubMed ID: 14534881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.